23andMe, Oscar Health among CNBC's top 50 'disruptors' for 2018

  • Small
  • Medium
  • Large

CNBC released its sixth annual Disruptor 50 list May 22, counting healthcare and biotechnology companies among its ranking of private companies "changing the world."

CNBC's Disruptor 50 Advisory Council — a group of 52 innovation and entrepreneurship experts — determined and ranked almost 1,000 nominations on various quantitative metrics to select the final 50. In total, CNBC's 50 selections have raised almost $78 billion in venture capital.

Here are six of CNBC's healthcare-related picks.

7. 23andMe (valuation: $1.8 billion). A direct-to-consumer genetic testing company that boasts FDA approval of at-home genetic tests for 10 diseases and a growing foundation in medical research.

12. Oscar Health (valuation: $3.2 billion). A health insurance company focused on leveraging technology and incentives to improve user experience.

15. Progyny (valuation: $123.1 million). A benefits startup that offers plans to self-insured companies to help employees cover the cost of fertility treatments, such as in-vitro fertilization and egg freezing.

25. Zipline International (valuation: N/A). A drone service that delivers medicine and blood supplies to difficult-to-reach places in developing countries around the globe.

30. Veritas Genetics (valuation: N/A). A genomics company that offers consumers and physicians the ability to sequence and interpret an individual's entire genome for under $1,000.

46. Auris Health (valuation: $1.3 billion). A robotic medical company developing microtools to enable more accurate diagnosis of lung cancer.

To access CNBC's Disruptor 50 list, click here.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars